Pressure to increase speed in the drug development process calls for more automation, more data and faster turnaround times. Solutions are required at the point of need, whether it is in research, process development or manufacturing. Data needs to be generated without the delay associated with sample transfer to central labs, decisions need to be made on the spot. Manual labour needs to be reduced for less errors and improved throughput. Amperia is our answer.
Performance alone is not enough. Simplicity and convenience is what make the difference. We built Amperia with the focus on effortless automation and simple workflow. The best way to experience it is to test it. That is why we believe that everyone should be able to test Amperia and see it for themselves. We offer a no-commitment, free of charge trial programme, to give everyone a chance to experience protein research made simple.
Ruizhi is the founder and CEO of Abselion. He has been leading the company since its founding, when it was still named HexagonFab. His responsibilities are directing all aspects of company strategy, planning, and operations.
Ruizhi has received a number of awards, both for his personal work and for his involvement at Abselion. These include the Emerging Technologies Award of the Royal Society of Chemistry, the Displaying Future Award of Merck Group and the Grand Price of the Cambridge University Entrepreneurs. He is also an Enterprise Fellow of the Royal Academy of Engineering and a recipient of the Scholarship of the German Academic Merit Foundation.
Ruizhi received his PhD from the University of Cambridge, and MSc./BSc. from ETH Zurich. He has co-authored 20 publications, with a total more than 700 citations.
VP of Science
Paolo is the VP of Science of Abselion. He is responsible for leading the research & development team in sensing, consumables, applications and assay development.
Prior to his current role, he worked at STMicroelectronics on the R&D of semiconductor devices. Paolo is a highly accomplished scientists in the area of non-optical biosensing. During his PhD, he conducted pioneering work on the principles of electrochemical detection of ions and proteins. This led to two first-author publications in Nature Communications, and multiple others in high impact journals.
Paolo received his PhD from the University of Brescia.
Business Development Manager
Ben is Senior Business Development Manager at Abselion, responsible for driving growth of sales and fostering new collaborations.
Ben has extensive experience with sales & marketing of laboratory instruments in the biotech sector, specifically in protein sciences and cell line development. In his previous role at Solentim he was responsible for a 400% increase of sales in the UK market. In addition he successfully identified and launched instruments into new market segments. Prior to that, he managed the sale of a portfolio of lab instruments at Cambridge Biosciences, exceeding sales targets multiple quarters in a row and leading in instrument sales per quarter company wide.
Ben’s commercial accolades revolve around creating significant growth strategies for equipment portfolios and increased territorial market shares to the point of acquisition.
Chairman of the Board
Simon has over 30 years’ experience in the biotech industry, including 10 years working for Amersham International (now GE), ICI and Zeneca (now Astra Zeneca), in a variety of commercial and technical positions, and over five years with Tepnel Life Sciences plc (now Hologic Inc), a London Stock Exchange listed diagnostic company where he was Chief Executive.
He has been the CEO/Executive Chairman of three other venture capital backed Life Science companies and headed up the trade sale of two of these and AIM listing of one. He is currently Chairman of two AIM listed companies, Fusion Antibodies plc, a CRO providing services for the discovery and development of antibody-based therapeutics and Omega Diagnostics Group plc, focussed on a personalised and functional approach to health and nutrition. He is also an advisor for Sensam Ltd, who are developing cancer screening tests based on the detection of volatile organic compounds.
Within her time at Cambridge Enterprise, she has worked with several University of Cambridge spin-out companies to develop investable propositions across Therapeutics, Life Sciences Technologies, Sustainability, AI and Drug Discovery, and Medtech.
Fátima works across all stages of the investment process from deal sourcing and due-diligence to negotiation and investment management. She supports her existing investments through strategic and operational input and currently sits on the boards of Semarion Ltd, HexagonFab Ltd, Colorifix Ltd and CamRegen Ltd.
As a keen networker, Fatima manages the engagement of national and international investors through the Cambridge Enterprise Venture Partners (CEVP) programme, and within Cambridge promotes interactions between spin-outs and Judge Business School students.
Prior to joining Cambridge Enterprise, Fátima worked for Oxford University Innovation, Cancer Research Horizons/CRUK and as Commercialisation Manager for the Babraham Institute in Cambridge. Her working career, however, started as a passionate researcher in Oxford where she held a MRC Career Development Fellowship after completing a DPhil from the Medical Sciences division also at the University of Oxford.
Fátima holds a Biology degree from the University of Porto.
Luke is an investor on BGF's early-stage team, with a focus on and life sciences and deep tech.
Prior to BGF, Luke headed up strategy and operations at Wren Therapeutics, a drug discovery company focused on neurodegenerative diseases. Before that, he was an early-stage investor at Ombu Group, where he also focused on life sciences and deep tech. He started his career at the Boston Consulting Group, working on strategy with senior management and boards across the energy and life sciences sectors.
Luke also holds a PhD in Biophysics from the University of Cambridge, where he led a range of projects focused on microfluidics technology and the biophysics of protein misfolding diseases.
TJ currently holds a number of roles, including Executive Chairman of Nonagen Bio, Non-Executive Chairman of MeCo Diagnostics and Advisor to Abselion.
Until 2022 TJ advised, then joined Codetta Bio as CEO to lead the startup of operations, and complete the product concept and proof of principle phases of product development. Before that TJ was CEO for HTG Molecular leading the company through a strategic restart, technology transition, successful IPO and 85% CAGR for the four years post IPO. Prior to HTG Mr. Johnson was an SVP with Ventana Medical Systems which grew revenue from $78M to over $250M and exited in 2007 for $3.4B. Prior to Ventana Mr. Johnson held numerous senior roles at Hill-Rom Company, a $1b market leader in hospital capital equipment and medical devices.
Founder & Advisor Technology
Stephan is the Professor of Nanotechnology of the University of Cambridge.
His research explores novel materials, metrology and device architectures. A particular focus thereby lies on nanomaterials. The nanometer dimensions can lead to extraordinary properties and being able to control and exploit those can have a transformative impact across a wide range of applications, such as information/communication technologies and life-sciences.
The vision of Dr Hofmann’s research is to unlock this huge technological potential through an unprecedented understanding of material design and functionality on the smallest of size scales.Dr Hofmann is leading a number of large research projects, funded eg by the ERC and EPSRC, with close industrial links and embedded in a large network of international collaborations.